- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Lisa M. Dwyer
News 32 results
In the News · Source: Law360 Healthcare Authority
July 22, 2025
Lisa Dwyer discusses the impact of the FDA recently publishing more than 200 rejection letters for new drug applications
In the News · Source: PharmaVoice
Recognition
June 11, 2025
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2025 Guide
In the News · Source: Law360 Healthcare Authority
Recognition
June 5, 2025
King & Spalding Earns 209 Lawyer Rankings, 100 Practice Group Rankings in Chambers USA Guide
In the News · Source: Pharma Voice and Corporate Counsel
In the News · Source: Pink Sheet
January 7, 2025
Lisa Dwyer discusses FDA’s final SIUU Guidance regarding off-label uses
In the News · Source: Law360 Healthcare Authority
December 17, 2024
Lisa Dwyer discuses FDA untitled letter trends regarding drug advertising and promotion
In the News · Source: Inside Health Policy
Recognition
June 12, 2024
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2024 Guide
In the News · Source: InsideHealthPolicy
May 21, 2024
Lisa Dwyer comments on the inherent risk of AI usage in clinical trial development